Skip to search.

Breaking News Visit Yahoo! News for the latest.

×Close this window

 Dow Up0.44% Nasdaq Up0.26%

Coronado Biosciences, Inc. (CNDO)

-NasdaqCM

9.84 Down 0.35(3.43%) 3:28PM EDT - Nasdaq Real Time Price

Add to Portfolio
ProfileGet Profile for:
Coronado Biosciences, Inc.
24 New England Executive Park
Suite 105
Burlington, MA 01803
United States - Map
Phone: 781-652-4500
Fax: 781-652-4545
Website: http://www.coronadobiosciences.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:16

Business Summary 

Coronado Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunotherapy biologic agents for the treatment of autoimmune diseases and cancer. Its principal pharmaceutical product candidates in clinical development include TSO or CNDO-201, which is a biologic comprising Trichuris suis ovathe, the microscopic eggs of the porcine whipworm, for the treatment of autoimmune diseases, such as Crohn’s disease, ulcerative colitis, multiple sclerosis, autism, psoriasis, type 1 diabetes, and rheumatoid arthritis; and CNDO-109, a biologic that activates the immune system’s natural killer, cells to seek and destroy cancer cells, for the treatment of acute myeloid leukemia. Coronado Biosciences, Inc. has collaboration agreement with Dr. Falk Pharma GmbH and OvaMed GmbH for the development of TSO to treat Crohn’s disease. The company was founded in 2006 and is based in Burlington, Massachusetts.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Coronado Biosciences, Inc.

Corporate Governance 
Coronado Biosciences, Inc.’s ISS Governance QuickScore as of May 1, 2013 is 5. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 2; Compensation: 5.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Dr. Harlan F. Weisman M.D., 61
Chairman and Chief Exec. Officer
17.00K0.00
Dr. Eric K. Rowinsky M.D., 56
Vice Chairman and Consultant
280.00KN/A
Dr. Lucy Lu M.D., 38
Chief Financial Officer and Exec. VP
350.00K0.00
Mr. Noah D. Beerman MBA, 51
Chief Operating Officer and Exec. VP
464.00K0.00
Mr. Dale Ritter , 62
Chief Accounting Officer and Sr. VP of Fin.
379.00K0.00
Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders